Tula M, Pazos M, Marín MB, Cohen SE, Cabo H

Language: Spanish
References: 17
Page: 46-51
PDF size: 377.10 Kb.

ABSTRACT

Classic acquired epidermolysis bullosa is a subepidermal autoimmune blistering disease of chronic course and low incidence. It presents with skin fragility and blisters of serohematic content in areas of friction or traumatism that evolve to hyperpigmentation and milia. The diagnosis is made through a correlation between clinical, histopathology and direct salt-split skin immunofluorescence. Although therapeutic management of acquired epidermolysis bullosa has been frequently difficult and unsuccessful, some satisfactory response has been described with certain medications such as colchicine. We report a case of a classic acquired epidermolysis bullosa with favorable drug-response to colchicines. An acquired epidermolysis bullosa classic case with a favorable drug-response evolution is introduced here.

REFERENCES

1. Le Roux-Villet C, Prost-Squarcioni C. Epidermolysis bullosa acquisita: literature review. Ann Dermatol Venereol. 2011; 138 (3): 228-246.

2. Roenigk HH Jr, Ryan JG, Bergfeld WF. Epidermolysis bullosa acquisita: report of three cases and review of all published cases. Arch Dermatol. 1971; 103 (1): 1-10.

3. Yaoita H, Briggaman RA, Lawley TJ, Provost TT, Katz SI. Epidermolysis bullosa acquisita: ultrastructural and immunological studies. J Invest Dermatol. 1981; 76 (4): 288-292.

4. Woodley DT, Briggaman RA, O’Keefe EJ, Inman AO, Queen LL, Gammon WR. Identification of the skin basement-membrane autoantigen in epidermolysis bullosa acquisita. N Engl J Med. 1984; 310 (16): 1007-1015.

5. Gammon WR, Heise ER, Burke WA, Fine JD, Woodley DT, Briggaman RA. Increased frequency of HLADR2 in patients with autoantibodies to epidermolysis bullosa acquisita antigen: evidence that the expression of autoimmunity to type VII collagen is HLA class II allele associated. J Invest Dermatol. 1988; 91 (3): 228-232.

6. Kim JH, Kim SC. Epidermolysis bullosa acquisita. J Eur Acad Dermatol Venereol. 2013; 27 (10): 1204-1213.

7. Chen M, Kim GH, Prakash L, Woodley DT. Epidermolysis bullosa acquisita: autoimmunity to anchoring fibril collagen. Autoimmunity. 2012; 45 (1): 91-101.

8. Ludwig RJ, Zillikens D. Pathogenesis of epidermolysis bullosa acquisita. Dermatol Clin. 2011; 29 (3): 493-501.

9. Kim JH, Kim YH, Kim SC. Epidermolysis bullosa acquisita: a retrospective clinical analysis of 30 cases. Acta Derm Venereol. 2011; 91 (3): 307-312.

10. Caux F. Diagnosis and clinical features of epidermolysis bullosa acquisita. Dermatol Clin. 2011; 29 (3): 485-491.

11. Gupta R, Woodley DT, Chen M. Epidermolysis bullosa acquisita. Clin Dermatol. 2012; 30 (1): 60-69.

12. Peña OJ, Chávez BJ. Epidermolisis bullosa adquirida: lo nuevo en biología molecular. Rev Cent Dermatol Pascua. 2011; 28 (2): 40-45.

13. Ishii N, Hamada T, Dainichi T, Karashima T, Nakama T, Yasumoto S et al. Epidermolysis bullosa acquisita: what’s new? J Dermatol. 2010; 37 (3): 220-230.

14. Intong LR, Murrell DF. Management of epidermolysis bullosa acquisita. Dermatol Clin. 2011; 29 (4): 643-647.

15. Arora KP, Sachdeva B, Singh N, Bhattacharya SN. Remission of recalcitrant epidermolysis bullosa acquisita (EBA) with colchicine monotherapy. J Dermatol. 2005; 32 (2): 114-119.

16. Sullivan TP, King LE Jr, Boyd AS. Colchicine in dermatology. J Am Acad Dermatol. 1998; 39 (6): 993-999.

17. Iranzo P, Herrero-González JE, Mascaró-Galy JM, Suárez-Fernández R, España A. Epidermolysis bullosa acquisita of 12 patients evaluated in four tertiary hospitals in Spain. Br J Dermatol. 2014; 171 (5): 1022-1030.